Kura Oncology, Kyowa Kirin announces FDA accepted NDA for ziftomenib
Kura Oncology (KURA) and Kyowa Kirin announced the U.S. Food and Drug Administration, FDA, has accepted Kura's New Drug Application, NDA, seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia with a nucleophosmin 1 mutation. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act, PDUFA, target action date of November 30, 2025. 'The FDA's acceptance of our New Drug Application marks a significant milestone for Kura and Kyowa Kirin and, more importantly, for patients living with this genetic subset of AML, who face an aggressive form of the disease with few treatment options,' said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. 'This achievement reflects the strength of the clinical data for ziftomenib as well as the incredible commitment of our teams. Along with our partners at Kyowa Kirin, we look forward to continuing to work closely with the FDA throughout the review process and to prepare for the anticipated launch of this treatment, which holds potential to meaningfully impact the lives of patients and their families.'
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
'Not recommended for human consumption' label may be required on chips, candies in Texas
A bill sitting on the desk of Texas Gov. Greg Abbott could force the food industry to digest the Make America Healthy Again movement. Texas Senate Bill 25 would require foods containing certain ingredients to have warning labels on their packaging. Some chips, candies and sodas would be required to bear the following label: "WARNING: This product contains an ingredient that is not recommended for human consumption." There are 44 ingredients listed, such as synthetic food dyes and bleached flour. M&M's would need the labeling in question, as they contain red 40, yellow 6 and blue dyes 1 and 2. Trix cereal contains blue 1 and red 40, while Doritos chips have red 40 and yellow 6 and 5. If signed into law, the legislation would require the label to be "placed in a prominent and reasonably visible location," the bill states. The bill states that the ingredients that should be disclosed are "any artificial color, food additive or other chemical ingredient banned by Canada, the European Union or the United Kingdom." Analysis behind the legislation found that 73% of the U.S. food supply is considered ultra-processed, with Americans' diet consisting of a 57% consumption of ultra-processed foods – "shown to be linked to depression, obesity, Type 2 diabetes, cancer and cardiovascular disease." "The industry is committed to transparency and has long invested in product transparency tools that help consumers to make informed choices for themselves and their families." In January, the FDA banned red dye 3, listed in the bill, from foods after being linked to cancer, as Fox News Digital previously reported. The Consumer Brands Association (CBA), which represents major food manufacturers such as General Mills and PepsiCo, are "urging" Abbott to veto the bill. "The labeling requirements of SB 25 mandate inaccurate warning language, create legal risks for brands and drive consumer confusion and higher costs," John Hewitt, senior vice president of state affairs, told Fox News Digital this week. "The industry is committed to transparency and has long invested in product transparency tools that help consumers to make informed choices for themselves and their families," Hewitt said. He added, "No industry is more committed to safety than the makers of America's trusted household brands. The ingredients used in the U.S. food supply are safe and have been rigorously studied following an objective science and risk-based evaluation process." In April, Fox News Digital asked U.S. Health and Human Resources Secretary Robert F. Kennedy about how Americans will be able to identify products that comply with the phase-out of petroleum-based dyes. "We're looking at labeling. We have to go to Congress for that — but one of the things that we're going to do is post all the information we have about every additive on an open-source website," he said. "And we're going to encourage companies … to develop apps in the private marketplace where mothers can go in and scan a barcode of every product in their grocery store and know what's in them and what's not." If signed by Abbott, food manufacturers would be required to add a label starting on Jan. 1, 2027.
Yahoo
an hour ago
- Yahoo
FastWave Medical completes initial procedures in study of IVL system
FastWave Medical has completed the initial first-in-human procedures in the multicentre feasibility study of the Sola coronary laser intravascular lithotripsy (IVL) system. The study is designed to evaluate the performance and safety of Sola in individuals with calcified coronary artery disease. According to the company, this rupture-resistant balloon catheter allows physicians to treat hardened calcium in blood vessels with control and precision. The system's laser energy claims to deliver a 360-degree pressure with every pulse, ensuring therapeutic consistency even in challenging lesions. Each energy pulse of the system delivers circumferential sonic pressure to any lesion for multidirectional, predictable performance. This latest development follows the company's first-in-human study of its peripheral electric IVL system, Artero, which demonstrated a complete procedural success rate without any adverse events observed at a 30-day follow-up. The findings from the Sola study are expected to inform the company's regulatory submissions and the design of its pivotal US trial, paving the way for obtaining approval from the Food and Drug Administration (FDA). FastWave Medical technology head Sukanya Iyer said: "Our team set out to reimagine what's possible with coronary IVL. "Seeing Sola perform in human cases reinforces our commitment to give clinicians cutting-edge tools for their high-risk patients." FastWave focuses on next-generation IVL technology, aiming at treating calcific artery disease in both peripheral and coronary applications. It has raised over $40m in venture financing to progress its dual-platform IVL systems. FastWave Medical COO Tristan Tieso said: "Every step of developing Sola has focused on solving the real-world problems physicians face in treating complex arterial disease.' Last month, the Institutional Review Board granted approval for the company to commence the coronary feasibility study using Sola. "FastWave Medical completes initial procedures in study of IVL system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
FDA deploys generative AI tool Elsa to transform agency operations in historic move
In a major step toward modernizing its operations, the U.S. Food and Drug Administration (FDA) on Monday launched Elsa, a generative artificial intelligence (AI) tool, designed to help agency employees, including scientific reviewers and field investigators, work smarter and faster. Elsa is the regulator's first large-scale foray into generative AI and is being dubbed as a turning point for the agency. Built in a secure GovCloud environment, the tool gives staff the ability to quickly search and summarize internal documents without compromising sensitive research and data handled by FDA staff. More than a chatbot, the tool also allows FDA scientists and subject-matter experts to spend less time on tedious, repetitive tasks that often slow down the review the AI models do not train on information submitted by regulated industries, ensuring the confidentiality of proprietary research. 'Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee,' the agency's Chief AI Officer, Jeremy Walsh, said. 'As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency.' The agency said it is already using the tool to speed up clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets. FDA Commissioner Dr. Marty Makary said the launch came ahead of schedule and under budget due to strong collaboration among internal teams. 'Following a very successful pilot program with FDA's scientific reviewers, I set an aggressive timeline to scale AI agency-wide by June 30,' he said. 'Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers.' Elsa is a large language model–powered AI tool designed to assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications. It is seen as the first step in a broader strategy to embed AI into FDA workflows. 'Prioritizing efficiency and responsibility, the FDA launched Elsa ahead of schedule using an all-center approach. Leaders and technologists across the agency collaborated, demonstrating the FDA's ability to transform its operations through AI,' the agency within the U.S. Department of Health and Human Services said in a release. As employees use the tool, its developers plan to expand capabilities to meet emerging needs. This includes improving usability, data processing, generative-AI functions, and tailoring outputs to center-specific needs while maintaining strict information security and compliance with FDA policy. The agency-wide rollout was coordinated by Walsh, the agency's newly-appointed Chief AI Officer, and Sridhar Mantha. Walsh previously led enterprise-scale technology deployments across federal health and intelligence agencies, and Mantha recently led the Office of Business Informatics in CDER.
